• Logo
  • SBMUJournals

Comparative study on guidelines in determining HBV phases in Iranian patients

Sara Ashtari, Afsaneh Sharifian, Behzad Hatami, Seyed Reza Mohebbi, GholamReza Nouri, Monireh Bazdar, Nosratollah Naderi
29

Views

PDF

Abstract

Aims: The aim of this study was to compare the different phases of chronic Hepatitis B virus (HBV) infection with different values for normal ALT.

 Background: For many years upper limit of 40 IU was considered normal for ALT for both sexes, but in recent years this value is challenged and some guidelines have lowered their limit.

 Methods: In this cross-sectional study, 2000 HBsAg positive patients who were referred to Taleghani Hospital, Tehran, Iran, from 2011 through 2018 were classified in four groups according to American Association of the study of the liver disease (AASLD), European Association of the study of the liver (EASL) /Asian-Pacific Association of the study of the liver (APASL) and American Collage of Gastroenterology (ACG) guidelines. Frequency of each group based on 3 different guidelines was compared.

Results: In HBeAg positive patients (n=100), percentage of immune tolerance phase was 43% according to AASLD cutoff for normal ALT (35 IU for men, 25 IU for women) while it was 68% and 28% with regard to EASL/APASL and ACG (30 IU for men, 19 IU for women) cutoffs respectively. In HBeAg negative patients (n=1900), 66.68% were inactive carriers according to AASLD but the percentage changed to 82.89% and 52.42% considering EASL/APASL and ACG values, respectively.

Conclusion: By using ACG and to a lesser extend AASLD cutoff for ALT, many patients shift from immune tolerance and inactive carrier state into immune active phase. Therefore more patients are candidates for treatment or intensive workup to determine extent of liver injury.


Keywords

Chronic hepatitis B, ALT level, CHB phases, Iran.

References

Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386:1546-55.

Poorolajal J, Majdzadeh R. Prevalence of chronic hepatitis B infection in Iran: a review article. J Res Med Sci 2009;14:249-58.

Mohammadi Z, Keshtkar A, Eghtesad S, Jeddian A, Pourfatholah AA, Maghsudlu M, et al. Epidemiological Profile of Hepatitis B Virus Infection in Iran in the Past 25 years; A Systematic Review and Meta-analysis of General Population Studies. Middle East J Dig Dis 2016;8:5-18.

Shakeri MT, Foghanian B, Nomani H, Ghayour-Mobarhan M, Nabavinia MS, Rostami S, et al. The prevalence of hepatitis B virus infection in mashhad, iran: a population-based study. Iran Red Crescent Med J 2013;15:245-8.

Salehi M, Alavian SM, Tabatabaei SV, Izadi S, Sanei Moghaddam E, Amini Kafi-Abad S, et al. Seroepidemiology of HBV infection in South-East of iran; a population based study. Iran Red Crescent Med J 2012;14:283-8.

Asadi-Lari M, Sayyari AA, Akbari ME, Gray D. Public health improvement in Iran--lessons from the last 20 years. Public Health 2004;118:395-402.

Mohaghegh Shelmani H, Karayiannis P, Ashtari S, Mahmanzar MA, Khanabadi B, Modami N, et al. Demographic changes of hepatitis B virus infection in Iran for the last two decades. Gastroenterol Hepatol Bed Bench 2017;10:S38-s43.

Croagh CM, Lubel JS. Natural history of chronic hepatitis B: phases in a complex relationship. World J Gastroenterol 2014;20:10395-404.

McMahon BJ. Natural history of chronic hepatitis B - clinical implications. Medscape J Med 2008;10:91.

Wu JF, Chang MH. Natural history of chronic hepatitis B virus infection from infancy to adult life - the mechanism of inflammation triggering and long-term impacts. J Biomed Sci 2015;22:92.

Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261-83.

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017.

Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1-98.

Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol 2017;112:18-35.

Keshavarz K, Kebriaeezadeh A, Alavian SM, Akbari Sari A, Abedin Dorkoosh F, Keshvari M, et al. Economic burden of hepatitis B virus-related diseases: evidence from iran. Hepat Mon 2015;15:e25854.

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-98.

Sharifian A, Naderi N, Sanati A, Mohebi SR, Azimzadeh P, Golmohamadi A, et al. The Early Results of a New Health Care Program Implementation in HBV Screening: an Iranian Experience. Middle East J Dig Dis 2015;7:226-32.

Sharifi Z. Natural history of chronic hepatitis B virus infection based on laboratory testing. Iran J Public Health 2014;43:990-3.

Keshvari M, Alavian SM, Sharafi H. Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients. Jundishapur J Microbiol 2015;8:e21444.

Cunha-Silva M, Marinho FRT, Oliveira PF, Lopes TM, Seva-Pereira T, Lorena SLS, et al. Retrospective analysis of hepatitis B virus chronic infection in 247 patients: clinical stages, response to treatment and poor prognostic factors. Braz J Infect Dis 2017.

Wang L, Zou ZQ, Wang K, Yu JG, Liu XZ. Role of serum hepatitis B virus marker quantitation to differentiate natural history phases of HBV infection. Hepatol Int 2016;10:133-8.

Chen P, Yu C, Wu W, Wang J, Ruan B, Ren J, et al. Serolological Profile Among HBsAg-Positive Infections in Southeast China: A Community-Based Study. Hepat Mon 2013;13:e7604.

Yapali S, Talaat N, Fontana RJ, Oberhelman K, Lok AS. Outcomes of patients with chronic hepatitis B who do not meet criteria for antiviral treatment at presentation. Clin Gastroenterol Hepatol 2015;13:193-201.e1.

Kemal Celen M, Tekin Koruk S, Aygen B, Dal T, Karabay O, Tosun S, et al. The characteristics of patients with chronic hepatitis B in Turkey. Med Glas (Zenica) 2014;11:94-8.

Saikia N, Talukdar R, Mazumder S, Khanna S, Tandon R. Management of patients with HBeAg-negative chronic hepatitis B. Postgrad Med J 2007;83:32-9.

Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010;51:1933-44.

Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989;2:588-91.

Ashtari S, Pourhoseingholi MA, Sharifian A, Zali MR. Hepatocellular carcinoma in Asia: Prevention strategy and planning. World J Hepatol 2015;7:1708-17.

El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27.

Kim DY, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012;1:2-14.

Parikh A, Taouli B. Imaging of hepatocellular carcinoma: current concepts. Recent Results Cancer Res 2013;190:33-55.




DOI: https://doi.org/10.22037/ghfbb.v12i0.1832